Objective: Immunohistochemistry plays an important role in diagnosis of Hodgkin lymphoma. Beyond diagnostic importance of Immunohistochemistry, so far many studies have investigated the correlation between cellular markers and the prognosis of patients with Hodgkin lymphoma. Amongst other markers, CD20 is one of the most studied marker with a lot of controversy around it. Method: Retrospectively 66 eligible patients entered the study. Clinical and laboratory Data and Immunohistochemistry findings analyzed for possible correlation between disease stage and other parameters. Results: In our study 63.6 %, 90.9 % of cases respectively expressed cellular markers CD15 and CD30 while only 18.2 % of cases expressed CD20. Furthermore statistical analysis revealed that CD15 was inversely correlated with disease staging. (P=0.027). In contrast we didn't find any relation between CD20 or CD30 positivity with disease staging. (P=0.482, P= 0.376). However in our study expression of CD20 was not related to stage or other parameters of poor prognosis which proposes that in our patients this marker possibly was not related to disease prognosis. Conclusion: Therefore we suggest that cellular marker CD20 is not beneficial beyond IPS factors and its usage should be confined to diagnostic purposes.